Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.
Under the deal terms, Disc Medicine will have exclusive rights to develop and market MWTX-003, as well as other new anti-TMPRSS6 monoclonal antibodies, discovered by Mabwell, in Europe, the US and other territories excluding China and some other territories in Southeast Asia.
By controlling iron homeostasis, MWTX-003 can address several hematologic disorders, such as polycythemia vera (PV) and beta-thalassemia.
It showed potent and durability in serum iron suppression and efficacy in animal models of beta-thalassemia and PV.
In November last year, the US Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for MWTX-003.
Disc Medicine intends to commence a Phase I study of MWTX-003 in healthy volunteers in the second half of the year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Disc Medicine CEO and president John Quisel said: “Disc has built deep expertise in the role of iron homeostasis in hematologic disorders, and I am thrilled to expand our portfolio with these highly complementary antibody programmes.
“We are delighted to be partnering with Mabwell, a company with a strong antibody technology platform that is led by Dr Xin Du, a leading expert on TMPRSS6 biology.
“This programme is in perfect alignment with our strategy and we look forward to advancing MWTX-003 into Phase I studies later this year.”
As per terms of the agreement, Mabwell will receive $10m in upfront cash payment and also be eligible for up to $412.5m development and commercial milestones.
Disc Medicine stated that the deal is subject to customary closing conditions and approval from Mabwell Therapeutics’s parent company Mabwell shareholders.